Patent · US Active

Bruton's tyrosine kinase inhibitor combinations and uses thereof

US9730938B2 · kind B2 · utility

11Cited by
1References
23Claims
0Family size

Assignees

Inventors

Key dates

Filing dateAug 6, 2015
Grant dateAug 15, 2017
Priority date—
Expiry dateAug 6, 2035

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.